Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
Total Valuation
Immunovant has a market cap or net worth of $2.50B. The enterprise value is $3.26B.
Market Cap$2.50B
Enterprise Value$3.26B
Share Statistics
Immunovant has 169,860,690 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding169,860,690
Owned by Insiders2.73%
Owned by Institutions24.73%
Financial Efficiency
Immunovant’s return on equity (ROE) is -0.42 and return on invested capital (ROIC) is -45.84%.
Return on Equity (ROE)-0.42
Return on Assets (ROA)-0.39
Return on Invested Capital (ROIC)-45.84%
Return on Capital Employed (ROCE)-0.46
Revenue Per Employee0.00
Profits Per Employee-1.25M
Employee Count207
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Immunovant is -16.83. Immunovant’s PEG ratio is -1.69.
PE Ratio-16.83
PS Ratio―
PB Ratio7.07
Price to Fair Value7.07
Price to FCF-20.34
Price to Operating Cash Flow-20.38
PEG Ratio-1.69
Income Statement
In the last 12 months, Immunovant had revenue of 0.00 and earned -259.34M in profits. Earnings per share was -1.88.
Revenue0.00
Gross Profit-231.00K
Operating Income-282.71M
Pretax Income-258.77M
Net Income-259.34M
EBITDA-269.98M
Earnings Per Share (EPS)-1.88
Cash Flow
In the last 12 months, operating cash flow was -324.94M and capital expenditures -708.00K, giving a free cash flow of -325.64M billion.
Operating Cash Flow-324.94M
Free Cash Flow-325.64M
Free Cash Flow per Share-1.92
Dividends & Yields
Immunovant pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.84
52-Week Price Change-46.45%
50-Day Moving Average17.85
200-Day Moving Average25.31
Relative Strength Index (RSI)41.22
Average Volume (3m)2.33M
Important Dates
Immunovant upcoming earnings date is May 28, 2025, TBA Not Confirmed.
Last Earnings DateFeb 6, 2025
Next Earnings DateMay 28, 2025
Ex-Dividend Date―
Financial Position
Immunovant as a current ratio of 13.70, with Debt / Equity ratio of <0.01%
Current Ratio13.70
Quick Ratio13.70
Debt to Market Cap<0.01
Net Debt to EBITDA2.35
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Immunovant has paid 567.00K in taxes.
Income Tax567.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Immunovant EV to EBITDA ratio is -13.82, with an EV/FCF ratio of -17.38.
EV to Sales0.00
EV to EBITDA-13.82
EV to Free Cash Flow-17.38
EV to Operating Cash Flow-17.41
Balance Sheet
Immunovant has $374.69M in cash and marketable securities with $23.00K in debt, giving a net cash position of -$374.66M billion.
Cash & Marketable Securities$374.69M
Total Debt$23.00K
Net Cash-$374.66M
Net Cash Per Share-$2.21
Tangible Book Value Per Share$4.47
Margins
Gross margin is 90.40%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin90.40%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Immunovant is $47.09, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$47.09
Price Target Upside219.90% Upside
Analyst ConsensusStrong Buy
Analyst Count13
Revenue Growth Forecast―
EPS Growth Forecast-43.10%